Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

Inclusion Criteria: * Age ≥ 3 years. (No dosing or adverse event data are currently available on the use of valganciclovir in patients \< 16 years of age.) * Life expectancy of \> 3 months. * ECOG Performance Status 0-2 or Karnofsky Performance Scale ≥ 60%. * Baseline (untransfused) HbF level \> 2% * Normal organ and marrow function defined as: (i) absolute neutrophil count of ≥ 1,000/µL. (ii) platelets ≥ 50,000/ µL. (iii) total bilirubin of ≤ 2.0 x upper limit of normal. (iv) AST (SGOT)/ALT(SGPT) of ≤ 2.0 x institutional upper limit of normal. (v) creatinine within normal range for institution. * Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. * Able and willing to give informed consent. Exclusion Criteria: * Patients that have received chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entry, or those who have not recovered form adverse events due to agents administered 4 weeks earlier. * Patients may not be receiving any other investigational agents. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Arginine Butyrate, ganciclovir or valganciclovir. * Patients who have an acute myocardial infarction or onset of atrial fibrillation within the past 6 months. * Uncontrolled intercurrent illness including, but not limited to , ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Tumor impinging on an organ or anatomical structure deemed critical by the investigator. * Pregnant women.